Gene Abnormality Found to Underlie Rare Neurological Disease
|
By LabMedica International staff writers Posted on 03 Nov 2016 |

Image: Motor neurons of Drosophila showing that expression of variant p.Arg534Trp of the fly’s equivalent of human ATAD3A gene causes a decrease in the number of mitochondria (green). Top row, control; middle row, motor neurons with normal (wild type) fly’s equivalent of human ATAD3A gene; bottom row, motor neurons with variant R534W of the fly’s equivalent of human ATAD3A gene. VNC, ventral nerve cord; Neurons are labeled in blue and boutons, an area of synapsis with another neuron, in red (Photo courtesy of The American Journal of Human Genetics).
Researchers have discovered that malfunctioning variants of a gene encoding a mitochondrial protein results in a group of related neurological syndromes classified as conditions of unknown origin. The study sheds new light on causes of such diseases and opens a door for developing better diagnostic tools and treatments.
Led by researchers from Baylor College of Medicine (Houston, TX, USA), the study has shown that this group of syndromes can result from variations in the gene ATAD3A encoding for the ATPase family AAA-domain containing protein 3A (ATAD3A), a nuclear-encoded mitochondrial membrane protein implicated in mitochondrial dynamics, nucleoid organization, protein translation, cell growth, and cholesterol metabolism.
“Through collaborative efforts with other teams, we identified a group of 5 non-related individuals with similar neurological characteristics of unknown origin. They had in common global developmental delay, low muscular tone and visual, neurological and heart problems,” said co-first author Tamar Harel, a genetics fellow at Baylor while working on this study, currently a geneticist at Hadassah Medical Center (Israel).
To investigate potential genetic causes “we sequenced the genes of each of the patients and by a process of comparison and elimination we found that the patients had in common the same new variant in this gene ATAD3A, but their parents did not. This indicated that this was a new mutation that had occurred in the children. We started as a fishing expedition but then we found this gene and decided to study it further,” said Dr. Harel.
“The gene became more and more interesting the more Tamar worked on it,” said senior author James Lupski, professor at Baylor, “Tamar was able to find that some patients had mutations in one copy of the gene, and this was enough to cause disease, while other patients had to have mutations in both copies of the gene to get disease. She also found families with one single error in the gene and others in which the disease was associated with a genomic copy number variant.”
Nevertheless, the human studies only revealed that the new ATAD3A variants were associated with neurological syndromes, not that they caused them. The scientists began a collaboration with co-author Hugo Bellen, professor at the Howard Hughes Medical Institute at Baylor, to combine the human studies with studies in the fruit fly Drosophila melanogaster as experimental model to help determine effects of the gene variants.
Co-first author Wan Hee Yoon, postdoctoral fellow in the Bellen lab, developed an ATAD3A disease model in D. melanogaster: “I expressed the normal, wild type protein in motor neurons and muscles of a group of flies, and the protein carrying the gene variant in the same tissues in other flies. We found that expression of the variant protein caused a dramatic decrease in the number of mitochondria, as well as an increase in mitophagy,” said Dr. Yoon.
In addition to generating energy as ATP, mitochondria are also essential for cellular metabolism as they generate building blocks needed to synthesize proteins and lipids. “The cell has a way to maintain its mitochondria healthy. One way is fusion and fission which allows cells to regenerate worn down mitochondria or to eliminate those that are not functional by digesting them and reusing their components, a process called mitophagy,” said Dr. Yoon, “Mitophagy is a critical process not only in neurological diseases, but also in other diseases such as cancer and other metabolic diseases.”
The scientists also examined fibroblasts from the patients. Comparing mitochondria in control versus in diseased fibroblasts they found that those in diseased fibroblasts were inside digestive vesicles, reflecting mitophagy. Mitophagy in fibroblasts from patients with ATAD3A variants was significantly higher than in control fibroblasts.
“The collective data indicate that mutations in ATAD3A can cause an aberrant phenotype in mitochondria and the flies are actually sick,” said Dr. Yoon. Combining the results of the human and fly studies increases confidence that the neurological syndromes observed in the study patients can be attributed at least in part to malfunctioning ATAD3A variants.
The study, by Harel T, Yoon WH, et al, was published online ahead of print September 15, 2016, in the American Journal of Human Genetics.
Related Links:
Baylor College of Medicine
Led by researchers from Baylor College of Medicine (Houston, TX, USA), the study has shown that this group of syndromes can result from variations in the gene ATAD3A encoding for the ATPase family AAA-domain containing protein 3A (ATAD3A), a nuclear-encoded mitochondrial membrane protein implicated in mitochondrial dynamics, nucleoid organization, protein translation, cell growth, and cholesterol metabolism.
“Through collaborative efforts with other teams, we identified a group of 5 non-related individuals with similar neurological characteristics of unknown origin. They had in common global developmental delay, low muscular tone and visual, neurological and heart problems,” said co-first author Tamar Harel, a genetics fellow at Baylor while working on this study, currently a geneticist at Hadassah Medical Center (Israel).
To investigate potential genetic causes “we sequenced the genes of each of the patients and by a process of comparison and elimination we found that the patients had in common the same new variant in this gene ATAD3A, but their parents did not. This indicated that this was a new mutation that had occurred in the children. We started as a fishing expedition but then we found this gene and decided to study it further,” said Dr. Harel.
“The gene became more and more interesting the more Tamar worked on it,” said senior author James Lupski, professor at Baylor, “Tamar was able to find that some patients had mutations in one copy of the gene, and this was enough to cause disease, while other patients had to have mutations in both copies of the gene to get disease. She also found families with one single error in the gene and others in which the disease was associated with a genomic copy number variant.”
Nevertheless, the human studies only revealed that the new ATAD3A variants were associated with neurological syndromes, not that they caused them. The scientists began a collaboration with co-author Hugo Bellen, professor at the Howard Hughes Medical Institute at Baylor, to combine the human studies with studies in the fruit fly Drosophila melanogaster as experimental model to help determine effects of the gene variants.
Co-first author Wan Hee Yoon, postdoctoral fellow in the Bellen lab, developed an ATAD3A disease model in D. melanogaster: “I expressed the normal, wild type protein in motor neurons and muscles of a group of flies, and the protein carrying the gene variant in the same tissues in other flies. We found that expression of the variant protein caused a dramatic decrease in the number of mitochondria, as well as an increase in mitophagy,” said Dr. Yoon.
In addition to generating energy as ATP, mitochondria are also essential for cellular metabolism as they generate building blocks needed to synthesize proteins and lipids. “The cell has a way to maintain its mitochondria healthy. One way is fusion and fission which allows cells to regenerate worn down mitochondria or to eliminate those that are not functional by digesting them and reusing their components, a process called mitophagy,” said Dr. Yoon, “Mitophagy is a critical process not only in neurological diseases, but also in other diseases such as cancer and other metabolic diseases.”
The scientists also examined fibroblasts from the patients. Comparing mitochondria in control versus in diseased fibroblasts they found that those in diseased fibroblasts were inside digestive vesicles, reflecting mitophagy. Mitophagy in fibroblasts from patients with ATAD3A variants was significantly higher than in control fibroblasts.
“The collective data indicate that mutations in ATAD3A can cause an aberrant phenotype in mitochondria and the flies are actually sick,” said Dr. Yoon. Combining the results of the human and fly studies increases confidence that the neurological syndromes observed in the study patients can be attributed at least in part to malfunctioning ATAD3A variants.
The study, by Harel T, Yoon WH, et al, was published online ahead of print September 15, 2016, in the American Journal of Human Genetics.
Related Links:
Baylor College of Medicine
Latest Molecular Diagnostics News
- Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test
- Blood Test Detects Early-Stage Cancers by Measuring Epigenetic Instability
- Two-in-One DNA Analysis Improves Diagnostic Accuracy While Saving Time and Costs
- “Lab-On-A-Disc” Device Paves Way for More Automated Liquid Biopsies
- New Tool Maps Chromosome Shifts in Cancer Cells to Predict Tumor Evolution
- Blood Test Identifies Inflammatory Breast Cancer Patients at Increased Risk of Brain Metastasis
- Newly-Identified Parkinson’s Biomarkers to Enable Early Diagnosis Via Blood Tests
- New Blood Test Could Detect Pancreatic Cancer at More Treatable Stage
- Liquid Biopsy Could Replace Surgical Biopsy for Diagnosing Primary Central Nervous Lymphoma
- New Tool Reveals Hidden Metabolic Weakness in Blood Cancers
- World's First Blood Test Distinguishes Between Benign and Cancerous Lung Nodules
- Rapid Test Uses Mobile Phone to Identify Severe Imported Malaria Within Minutes
- Gut Microbiome Signatures Predict Long-Term Outcomes in Acute Pancreatitis
- Blood Test Promises Faster Answers for Deadly Fungal Infections
- Blood Test Could Detect Infection Exposure History
- Urine-Based MRD Test Tracks Response to Bladder Cancer Surgery
Channels
Clinical Chemistry
view channel
New PSA-Based Prognostic Model Improves Prostate Cancer Risk Assessment
Prostate cancer is the second-leading cause of cancer death among American men, and about one in eight will be diagnosed in their lifetime. Screening relies on blood levels of prostate-specific antigen... Read more
Extracellular Vesicles Linked to Heart Failure Risk in CKD Patients
Chronic kidney disease (CKD) affects more than 1 in 7 Americans and is strongly associated with cardiovascular complications, which account for more than half of deaths among people with CKD.... Read moreHematology
view channel
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read more
Fast and Easy Test Could Revolutionize Blood Transfusions
Blood transfusions are a cornerstone of modern medicine, yet red blood cells can deteriorate quietly while sitting in cold storage for weeks. Although blood units have a fixed expiration date, cells from... Read more
Automated Hemostasis System Helps Labs of All Sizes Optimize Workflow
High-volume hemostasis sections must sustain rapid turnaround while managing reruns and reflex testing. Manual tube handling and preanalytical checks can strain staff time and increase opportunities for error.... Read more
High-Sensitivity Blood Test Improves Assessment of Clotting Risk in Heart Disease Patients
Blood clotting is essential for preventing bleeding, but even small imbalances can lead to serious conditions such as thrombosis or dangerous hemorrhage. In cardiovascular disease, clinicians often struggle... Read moreImmunology
view channelBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read moreMicrobiology
view channel
Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease
Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read moreAI-Powered Platform Enables Rapid Detection of Drug-Resistant C. Auris Pathogens
Infections caused by the pathogenic yeast Candida auris pose a significant threat to hospitalized patients, particularly those with weakened immune systems or those who have invasive medical devices.... Read morePathology
view channel
Engineered Yeast Cells Enable Rapid Testing of Cancer Immunotherapy
Developing new cancer immunotherapies is a slow, costly, and high-risk process, particularly for CAR T cell treatments that must precisely recognize cancer-specific antigens. Small differences in tumor... Read more
First-Of-Its-Kind Test Identifies Autism Risk at Birth
Autism spectrum disorder is treatable, and extensive research shows that early intervention can significantly improve cognitive, social, and behavioral outcomes. Yet in the United States, the average age... Read moreTechnology
view channel
Robotic Technology Unveiled for Automated Diagnostic Blood Draws
Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more
ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
Clinical laboratories generate billions of test results each year, creating a treasure trove of data with the potential to support more personalized testing, improve operational efficiency, and enhance patient care.... Read moreAptamer Biosensor Technology to Transform Virus Detection
Rapid and reliable virus detection is essential for controlling outbreaks, from seasonal influenza to global pandemics such as COVID-19. Conventional diagnostic methods, including cell culture, antigen... Read more
AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests
Pre-eclampsia and anemia are major contributors to maternal and child mortality worldwide, together accounting for more than half a million deaths each year and leaving millions with long-term health complications.... Read moreIndustry
view channelNew Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing
Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
AI-Powered Cervical Cancer Test Set for Major Rollout in Latin America
Noul Co., a Korean company specializing in AI-based blood and cancer diagnostics, announced it will supply its intelligence (AI)-based miLab CER cervical cancer diagnostic solution to Mexico under a multi‑year... Read more
Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform
Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more







